Price Alert

Horizon Therapeutics Publ... (HZNP)

NASDAQ: HZNP · Real-Time Price · USD

116.30

0.00 (0.00%)

At close: Jan 16, 2025, 10:00 PM

Horizon Therapeutics Public Statistics

Share Statistics

Horizon Therapeutics Public has 228.74M shares outstanding. The number of shares has increased by -0.39% in one year.

Shares Outstanding	228.74M
Shares Change (YoY)	-0.39%
Shares Change (QoQ)	0%
Owned by Institutions (%)	n/a
Shares Floating	211.06M
Failed to Deliver (FTD) Shares	490
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 7.71M, so 0% of the outstanding shares have been sold short.

Short Interest	7.71M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.91

Valuation Ratios

The PE ratio is 50 and the forward PE ratio is null. Horizon Therapeutics Public's PEG ratio is -13.17.

PE Ratio	50
Forward PE	n/a
PS Ratio	7.18
Forward PS	n/a
PB Ratio	5.14
P/FCF Ratio	23.04
PEG Ratio	-13.17

Financial Ratio History

Enterprise Valuation

Horizon Therapeutics Public has an Enterprise Value (EV) of 26.28B.

EV / Sales	7.24
EV / EBITDA	23.58
EV / EBIT	20.89
EV / FCF	23.23

Financial Position

The company has a current ratio of 3.85, with a Debt / Equity ratio of 0.51.

Current Ratio	3.85
Quick Ratio	3.67
Debt / Equity	0.51
Debt / EBITDA	2.3
Debt / FCF	2.26
Interest Coverage	7.38

Financial Efficiency

Return on Equity is 10.28% and Return on Invested Capital is 7.47%.

Return on Equity	10.28%
Return on Assets	5.72%
Return on Invested Capital	7.47%
Revenue Per Employee	$1.66M
Profits Per Employee	$238.12K
Employee Count	2,190
Asset Turnover	0.4
Inventory Turnover	5.43

Taxes

Income Tax	5.45M
Effective Tax Rate	1.04%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is 1.01, so Horizon Therapeutics Public's price volatility has been higher than the market average.

Beta	1.01
52-Week Price Change	n/a
50-Day Moving Average	110.46
200-Day Moving Average	108.27
Relative Strength Index (RSI)	83.96
Average Volume (20 Days)	23,917,757

Income Statement

In the last 12 months, Horizon Therapeutics Public had revenue of 3.63B and earned 521.48M in profits. Earnings per share was 2.28.

Revenue	3.63B
Gross Profit	2.71B
Operating Income	617.41M
Net Income	521.48M
EBITDA	1.11B
EBIT	610.64M
Earnings Per Share (EPS)	2.28

Full Income Statement

Balance Sheet

The company has 2.35B in cash and 2.56B in debt, giving a net cash position of -210M.

Cash & Cash Equivalents	2.35B
Total Debt	2.56B
Net Cash	-210M
Retained Earnings	590.01M
Total Assets	9.3B
Working Capital	3B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.26B and capital expenditures -126.28M, giving a free cash flow of 1.13B.

Operating Cash Flow	1.26B
Capital Expenditures	-126.28M
Free Cash Flow	1.13B
FCF Per Share	4.94

Full Cash Flow Statement

Margins

Gross margin is 74.64%, with operating and profit margins of 17.01% and 14.37%.

Gross Margin	74.64%
Operating Margin	17.01%
Pretax Margin	14.52%
Profit Margin	14.37%
EBITDA Margin	30.71%
EBIT Margin	17.01%
FCF Margin	31.18%

Dividends & Yields

HZNP does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	2%
FCF Yield	4.34%

Dividend Details

Analyst Forecast

Currently there are no analyst rating for HZNP.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	33.67
Graham Upside	-71.05%

Scores

Altman Z-Score	5.08
Piotroski F-Score	8